8 August 2023 - The US is expanding public investment in the technology-based industries, including the life sciences, in a move driven by anger, fear, and hope. 

Anger at high drug prices is leading to downward pressures and eroding traditional private-sector funding for research and development, fear of China’s technological and political ambitions is creating bipartisan support for intervention, and the successful development of COVID-19 vaccines has spurred hope for analogous publicly funded breakthroughs in other therapeutic domains.

Read Health Affairs article